Jingfang Ju, Ph.D., Associate Professor.
Jingfang Ju, Ph.D.
Assistant Professor
Co-director of Translational Research Laboratory
Stony Brook University Medical Center
State University of New York at Stony Brook
Stony Brook, NY 11794-8691
Tel: (631) 444-2176
Fax: (631) 444-3424
e-mail: jiju@notes.cc.sunysb.edu
Education:
| 1985-1989 | B.S., Chemical Engineering, Northeastern University, P. R. China |
| 1990-1992 | M.S., Applied Chemistry, New Mexico Highlands University, NM |
| 1992-1996 | Ph.D., Molecular Biology and Biochemistry, University of Southern California, School of Medicine, Los Angeles, CA |
| 1996-1999 | Post-doc., Molecular Pharmacology. Yale University, School of Medicine, CT |
Professional Positions:
| 1999-2003 | Senior Research Scientist and Genomic Technology Team Leader, CuraGen Inc., CT |
| 2004-2008 | Head of the Cancer Genomics, Assistant Professor of Oncological Sciences, Mitchell Cancer Institute, Mobile, AL |
Awards and Honors:
| 2007 | Editorial Board, Cancer Genomics and Proteomics |
| 2006 | Editorial board, Gene Regulation and Systems Biology |
| 2006 | Managing Editor, Frontiers in Biosciences |
| 2007 | Scientific Advisory Board of International Institute of Anticancer Research |
| 2004-present | Member of NCI Innovative Molecular Analysis Technology (IMAT) Review Panel |
| 2005 | Member of NCI K- and R- Training Grant Review Panel |
| 2004-present | Member of NCI Emerging Technology for Cancer Research Review Panel |
| 2004 | Member of NCI Biomarker Special Review Panel |
| 2000 | Employee Achievement Award, CuraGen Corporation |
| 1999 | National Research Service Award, NIH |
| 1996 | Glaxo Welcome Oncology Clinical Research Scholar Award |
Research Interests:
Dr. Ju’s research at Stony Brook University School of Medicine focuses on elucidating the mechanism of translational control mediated by miRNAs in cancer and translating the new discovery to clinical diagnosis. His group is the first to discover that p53 regulates the expression of certain miRNAs, opening a new frontier in cancer research. They are actively investigating the mechanism of candidate miRNAs that potentially interact with p53. His group is also developing novel approaches to study post-transcriptional control mediated by miRNAs. As for the translational research, they are interested in the investigation of miRNAs as biomarkers in cancer diagnosis and prognosis.
Selected Publications:
Song B, Wang Y, Kudo K, Gavin EJ, Xi Y, Ju J. miR-192 regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clinical Cancer Research 2008;14(24):8080-6.
Riker AI, Enkemann S, Liu S, Ren S, Morris C, Xi Y, Howell P, Li W, Samant R, Shevde L, Ju J, Fodstad O, Matta J. Gene expression patterns at different stages of progression in human melanoma. BMC Medical Genomics. 2008 Apr 28;1(1):13.
Gavin EJ, Song B, Wang Y, Xi Y, Ju J. Reduction of Orc6 expression sensitizes human colon cancer cells to 5-fluorouracil and cisplatin. PLoS ONE. 2008;3(12):e4054.
Xi Y, Formentini A, Nakajima G, Kornmann M, Ju J. Characterization and validation of genes associated with 5-FU and thymidylate synthase in colorectal cancer. Oncology Reports. 2008, 19(1): 267-262.
Xi Y, Riker A, Shevde-Samant L, Samant R, Morris C, Gavin E, Fodstad O, Ju J. Global comparative gene expression analysis of melanoma patient samples, derived cell lines and corresponding tumor xenografts. Cancer Genomics & Proteomics. 2008, 5(1):1-35.
Xi Y*, Nakajima G*, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J. Systematic analysis of microRNAs expression of RNA extracted from fresh frozen and formalin fixed paraffin embedded samples. RNA. 2007. 13(10):1668-74.
Ju J, Schmitz JC, Song B, Kudo K, Chu E. Regulation of p53 expression in response to 5-FU in human colon cancer RKO cells. Clinical Cancer Research. 2007. 13(14); 4245-4251.
Xi Y, Edward JR, Ju J. Investigation of miRNA biology by bioinformatics tools and impact of miRNAs in colorectal cancer - regulatory relationship of c-myc and p53 with miRNAs. Cancer Informatics. 2007 3: 245-253.
Xi Y, Nakajima G, Hamil T, Fodstad O, Riker A, Ju J. Association of insulin-like growth factor binding protein-3 expression with melanoma progression. Molecular Cancer Therapeutics. 2006; 5(12): 3078-3084.
Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Ju J. Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics & Proteomics. 2006; 3: 317-324.
Xi Y, Formentini A, Chien M, Weir D, Russo, JJ, Ju J, Kornmann M, Ju J. Noncoding miRNAs as prognostic factors in colorectal cancer. Biomarker Insights. 2006; 2: 113-121.
Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J. Differentially regulated miRNAs and actively translated mRNA transcripts by tumor suppressor p53 in colon cancer. Clinical Cancer Research. 2006; 12 (7): 2014-2024.
Xi Y, Nakajima G, Schmitz, JC, Chu E, Ju J. Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics. 2006: 7: 68.
Ju J, Huang C, Minskoff SA, Mayotte JE, Taillon BE, Simons JF. Simultaneous gene expression analysis of steady-state and actively translated mRNA populations from osteosarcoma MG-63 cells in response to IL-1alpha via an open expression analysis platform. Nucleic Acids Res. 2003; 31(17): 5157-66.
Schmittgen TD, Ju J, Danenberg KD, Lenz HJ, Danenberg PV. Inhibition of pre-mRNA splicing by cisplatin and platinum analogs. Int J Oncol. 2003; 23(3): 785-789.
Chu E, Copur SM, Ju J, Carey KL, Khleif S, Voeller DM, Mizunuma N, Patel M, Maley GF, Maley F, Allegra C. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol. Cell. Biol. 1999; 19: 1582-1594.
Ju J, Lane J-P, Maley F, Chu E. Translational regulation of p53 expression by thymidylate synthase. Proc. Natl. Acad. Sci. USA 1999; 96: 3769-3774.
Chu E, Schmitz J, Ju J. Molecular regulation of expression of thymidylate synthase. Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy (Humana Press Inc., Totowa, NJ). 1999; 397-408.
Liu M, Pelling JC, Ju J, Chu E, Brash DE. Antioxidant action via p53-mediated apoptosis. Cancer Research. 1998, 1723-1729.
Ju J, Lenz HJ, Banerjee D, Danenberg KD, Schmittgen T, Spears CP, Schonthal AH, Leichman L, Bertino JR, Danenberg PV. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multi-drug sensitivity. Clinical Cancer Research. 1998; 4: 1315-1322.
Ju J, Kane SE, Lenz HJ, Chu E, Danenberg KD, Danenberg PV. Desensitization and sensitization of tumors to fluoropyrimidines with antisense against thymidylate synthase.Clinical Cancer Research. 1998; 9: 2229-2236.
Banerjee D, Lenz H-F, Schnieders B, Manno D, Ju J, Spears CP. Hochhauser D, Danenberg KD, Danenberg PV, Bertino JR. Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL-60 cells and increases their sensitivity to stress. Molecular Cancer Research. 1995. 6(11):1405-13.
Last updated by andrea.schmidt on September 29, 2009